There was significant heterogeneity ( p < 0.001 ) in the efficacy of an early invasive strategy compared to standard therapy , between the strata with GPIIb/IIIa inhibitor use ( primary end point 9.6 % vs 22.3 % respectively , p < 0.001 ) and without GPIIb/IIIa inhibitor use ( primary end point 14.8 % vs 10.4 % respectively , p = 0.21 ) .